CN:ARCA-Deutsche X-trackers MSCI All China Equity (USD)

ETF | China Region | NYSE Arca

Last Closing

USD 0.14

Change

-0.01 (-3.45)%

Market Cap

USD 4.59M

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks investment results that correspond to the performance, before fees and expenses, of the MSCI China All Shares Index. The fund will normally invest at least 80% of its total assets in securities of issuers that comprise either directly or indirectly the underlying index or securities with economic characteristics similar to those included in the underlying index. The underlying index is designed to capture large- and mid-capitalization representation across all China securities listed in Hong Kong, Shanghai and Shenzhen. It is non-diversified.

Inception Date: 29/04/2014

Primary Benchmark: MSCI China All Shares NR USD

Primary Index: MSCI ACWI Ex USA NR USD

Gross Expense Ratio: 0.6%

Management Expense Ratio: 0.28 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings
Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for China Region

Symbol Name Mer Price(Change) Market Cap
KWEB KraneShares CSI China Internet.. 0.75 %

N/A

USD 5.72B
FXI iShares China Large-Cap ETF 0.74 %

N/A

USD 4.39B
EWT iShares MSCI Taiwan ETF 0.59 %

N/A

USD 4.11B
ASHR Xtrackers Harvest CSI 300 Chin.. 0.65 %

N/A

USD 1.69B
CQQQ Invesco China Technology ETF 0.70 %

N/A

USD 0.60B
EWH iShares MSCI Hong Kong ETF 0.48 %

N/A

USD 0.49B
GXC SPDR® S&P China ETF 0.59 %

N/A

USD 0.48B
CHIQ Global X MSCI China Consumer D.. 0.65 %

N/A

USD 0.23B
FLTW Franklin FTSE Taiwan ETF 0.19 %

N/A

USD 0.20B
KBA KraneShares Bosera MSCI China .. 0.60 %

N/A

USD 0.19B

ETFs Containing CN

N/A

Market Performance

  Market Performance vs. Industry/Classification (China Region) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -99.43% 5% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.43% 5% F N/A F
Trailing 12 Months  
Capital Gain -99.53% 5% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.53% 5% F N/A F
Trailing 5 Years  
Capital Gain -99.60% 5% F N/A F
Dividend Return 8.83% 70% C- 32% F
Total Return -90.77% 5% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -3.21% 43% F 27% F
Dividend Return -1.43% 43% F 22% F
Total Return 1.78% 62% D 44% F
Risk Return Profile  
Volatility (Standard Deviation) 26.22% 57% F 43% F
Risk Adjusted Return -5.45% 38% F 25% F
Market Capitalization 4.59M 14% F 5% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.